Five Pharma stocks see price target cuts, some downgraded by Macquarie

BMS, the American pharmaceutical firm, reached agreements with several generic companies to distribute restricted quantities of generic Revlimid in the US beginning March 2022.

BMS, the American pharmaceutical firm, reached agreements with several generic companies to distribute restricted quantities of generic Revlimid in the US beginning March 2022.

Gautam Duggad, Head of Research, Institutional Equities at Motilal Oswal Financial Services, expects 10% earnings growth in their coverage universe and 5% for the Nifty in April–June quarter of 2025(Q1FY26). He believes these numbers will improve in the coming quarters.

Total volumes grew 11.3% year-on-year to 12.90 lakh TEUs, compared to 11.59 lakh TEUs in the same period last year. Domestic volumes rose 9%, while export-import (EXIM) volumes increased 12% year-on-year.

Among the Tier-1 IT companies, Infosys is expected to lead revenue growth of 1.5% quarter-on-quarter in constant currency terms aided by seasonality and weak base of Q4FY25.

SEBI is considering a proposal to link options trading leverage to corresponding cash market positions, in a move aimed at curbing speculation and boosting equity market liquidity, sources said. The board may also discuss reforms to short-selling and the SLBM…

A study released by SEBI on Monday evening disclosed that nine out of every 10 retail traders continued to lose money in the Equity Derivatives Market.

Under existing rules, AMCs can only manage broad-based funds—those with 20 or more investors and no single investor holding more than 25% of the assets—unless they apply for a PMS license, which allows performance-linked fees and less regulated structures.

NBCC is now covered by four analysts, of which three of them have a “buy” rating and one has a “sell” recommendation.

As of 11 AM, 13.3 crore shares of PC Jeweller have already been traded, following Monday’s 64 crore shares and 49.5 crore shares last Friday. The 20-day average trading volume for this stock is 2.5 crore shares.

Of the 31 analysts that have coverage on the stock, 14 have a “buy” rating, seven have a “hold” rating and 10 have a “sell” rating.